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Abstract
The nematode worm Caenorhabditis elegans has become an intensely studied model organism, and
worm studies have made significant contributions to developmental biology and other fields. The
experimental advantages of C. elegans, particularly its simple anatomy, optical transparency, short
lifespan, and facile genetics, have also led researchers to use this model to investigate neuronal cell
degeneration and death. Worm studies of neurodegeneration can be divided into two general
classes: studies in which mutations of C. elegans genes lead to neuronal dysfunction and death, and
studies in which external manipulations (e.g., chemical treatments or introduction of engineered
transgenes) are used to induce neurodegeneration. For both types of studies the primary approach
has been to use forward genetic, reverse genetic, or candidate gene approaches to identify genes
that modify neurodegeneration. The ease and relatively low cost of C. elegans propagation also
suggests a role for these C. elegans models for compound screening. An excellent review has been
previously published that summarizes much of the work done on mutationally-induced neuronal
death in C. elegans [1]. This review focuses on studies that have attempted to model specific human
neurodegenerative diseases using transgenic approaches. These studies have given us a variety of
insights into the specific disruptions of cellular processes that may underlie human
neurodegenerative diseases.
Are worm models of human neurodegenerative 
diseases a good idea?
Although invertebrate model systems (e.g., C. elegans or
Drosophila) have significant experimental advantages, it is
not self-evident that they are good approaches to study
human neurodegeneration. As detailed below for C. ele-
gans, there is strong support for the conservation of basic
neuronal cellular functions between invertebrates and
vertebrates. The critical question is therefore whether the
specific neuronal cellular functions that are directly per-
turbed in neurodegenerative diseases are also conserved
between these model systems and people. Given that the
causal molecular/cellular insults underlying neurodegen-
erative conditions are not known (or at least controver-
sial), the answer to this question is unclear. It is clear,
though, that expression of specific human proteins linked
to neurodegeneration (e.g., β-amyloid peptide, tau, α-
synuclein, etc.) leads to cellular toxicity in worms and
flies. Minimally, invertebrate models should give us
insight into (at least some) toxic activities of disease-rele-
vant human proteins. The relevance of neurotoxic mecha-
nisms established in worm or fly models necessarily need
to be validated in mammalian systems. Thus, it is perhaps
best to view worm models of neurodegeneration as
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"scout" systems that have the potential to generate impor-
tant findings regarding mechanisms of neurotoxicity, with
the caveat that all findings are probably provisional until
extended to mammalian systems.
A major challenge in generating a worm neurodegenera-
tion model is obtaining evidence that any observed
pathology is specific and disease-relevant. One such piece
of evidence for transgenic models is the demonstration
that disease proteins containing mutations associated
with familial forms of the disease are more toxic than wild
type when expressed in worms [e.g., α-synuclein contain-
ing familial Parkinson's disease (PD) substitutions should
be more toxic than wild type α-synuclein]. In addition,
demonstrating that a disease model shows the same spec-
trum of neurotoxicty (e.g., preferential toxicity to
dopaminergic neurons in PD models) and/or similar cell
pathology (e.g., formation of Lewy body-like inclusions in
PD models) as observed in the human disease also
strengthens the case for the relevance of a model. It is rea-
sonable to assume that worm models with cellular (or
molecular) pathology more similar to the human disease
have a stronger "presumption of relevance".
The strongest argument for developing worm models of
neurodegeneration is that worms are amenable to unbi-
ased genetic approaches, classically based on identifying
forward mutations that modify the phenotype presented
by a given model. In recent years this approach has been
extended by using reverse genetic techniques such as RNA
interference (RNAi). The value of these unbiased
approaches lies in the two possible outcomes of a success-
ful screen: either a gene previously linked to the disease is
found, or a novel interactor is identified. In the first case
the result strengthens previous findings, in the later case
new insights may be gained. (Possibility #2 is a corollary
of a creed in the field: genetics is a way to answer ques-
tions you weren't smart enough to ask in the first place.)
Of course, novel findings from worm models require extra
skepticism and validation.
Additional advantages of worm models include the short
lifecycle/lifespan and the ability to generate transgenic
strains relatively rapidly. At 20°C, the most common cul-
ture condition for C. elegans, the life cycle takes approxi-
mately 4 days and the mean lifespan is about 17 days.
Thus, strains containing heritable (although typically
unstable) transgenes can be constructed by microinjection
in two weeks. (Derivation of completely stable, chromo-
somally integrated transgenes typically takes another
month.) Combined with the ability to readily freeze and
recover transgenic strains, it is feasible to generate large
collections of strains expressing related transgenes [e.g., a
series of engineered mutations in a protein or promoter
region, a collection of Green Fluorescent Protein (GFP)
reporters for a set of related genes, etc.]. This capacity
allows comparative studies that would be very expensive
and time-consuming to do in mice.
Although typically propagated on small agar-filled Petri
plates, C. elegans can also be grown in microtiter wells,
suggesting that worm models could be particularly appro-
priate for high-throughput drug screens.
Relevant neuroanatomy of C. elegans
Adult C. elegans hermaphrodites contain only 302 neu-
rons, and the complete pattern of synaptic connections
has been reconstructed by serial electron microscopy.
Neuronal classes include chemosensory, mechanosen-
sory, and thermosensory types; 75 motor neurons inner-
vate the body wall muscles (excluding the head); 56 of
these are cholinergic and 19 are GABAnergic. C. elegans
larvae contain 4 serotonergic and 8 dopaminergic neu-
rons. Formation, trafficking, and release of synaptic vesi-
cles in C. elegans is highly conserved, employing many of
the same proteins as are used in mammalian neurons.
Because C. elegans is transparent throughout its life cycle,
GFP fusions have been extensively used to visualize spe-
cific neurons and synapses in living animals. In some
instances, neuronal death can be directly observed in liv-
ing worms by the appearance of vacuolated neurons.
More generally, GFP tagging of specific neurons allows
observation of neuronal cell dystrophy or loss throughout
the lifetime of the animal.
There are limitations to studying neurodegeneration in C.
elegans. Worms do not have myelination or an active
immune system, so they are presumably not appropriate
for some neurodegenerative conditions such as multiple
sclerosis. Practically, worm neurons are small and difficult
to patch clamp, although recordings can be made from
single identified neurons [2]. RNA interference (RNAi), a
particularly useful tool in C. elegans, is often ineffective in
neurons, necessitating the introduction of additional
mutations to enhance neuronal RNAi efficacy.
What can we expect to learn from worm models 
of neurodegeneration?
Essentially all of the major age-associated neurodegenera-
tive diseases (e.g., Alzheimer's, Parkinson's, ALS, etc.)
have been linked to accumulation of specific proteins in
the CNS. The neurodegenerative process in these diseases
can be viewed as having three phases: accumulation of the
toxic protein, toxic insult to neurons, and neuronal dys-
function and death. In theory, components in any of these
phases can be identified by the identification of modifier
genes in worm models of neurodegenerative diseases.
This review will focus on a subset of C. elegans studies to
illustrate how worm neurodegeneration models have
been used to identify components of these phases of neu-
rodegeneration. An inclusive list of studies employingMolecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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transgenic C. elegans strains to study specific neurodegen-
erative diseases is shown in Table 1.
Polyglutamine repeat diseases
In 1999, Hart and colleagues described a C. elegans Hunt-
ington's disease (HD) model based on expression of a
huntingtin fragment (exon 1) containing a 150 repeat
polyglutamine (Ht-Q150) expansion [3]. Expression of
this huntingtin fragment was driven by the osm-10 pro-
moter, resulting in expression specifically in (non-essen-
tial) sensory neurons. Ht-Q150 expression was found to
induce both neuronal dysfunction (demonstrated by the
inability of chemosensory neurons to take up fluorescent
dyes) and eventual death of chemosensory neurons
(under conditions of osm-10::GFP co-expression). The
apparent toxicity of Ht-Q150 was age-dependent but rela-
tively mild, such that 13% of transgenic worms had dye
uptake abnormalities at day 8 of development (mid-
adulthood). This transgenic phenotype was subsequently
used to identify mutations that enhanced Ht-Q150 toxic-
ity, leading to the identification of pqe-1 [4]. Loss-of-func-
tion mutations in pqe-1  were found to dramatically
enhance Ht-Q150-dependent chemosensory neuron
death. pqe-1 encodes a nuclear protein rich in glutamines
and prolines that also contains a conserved exonuclease
domain (although PQE-1-homologous protein exist in
mammals and flies, these proteins do not appear to con-
tain glutamine/proline-rich domains). Given the cellular
distributions of PQE-1 and Ht-Q150, these authors
argued that wild type PQE-1 protein may protect from Ht-
Q150 toxicity by competing for proteins sequestered by
Ht-Q150.
The osm-10/Ht-Q150 model has also been used to investi-
gate the roles of specific histone deacetylases in regulating
huntingtin polyglutamine (Ht-polyQ) toxicity [5]. Studies
in multiple models have demonstrated that expanded
polyglutamine huntingtin can sequester CREB-binding
Table 1: C. elegans transgenic models for human neurodegenerative diseases.
Neurodegeneration-associated protein Transgene expression Promoter Sequence References
Huntingtin::polyQ chemosensory neurons osm-10 Faber et al [3]
mechanosensory neurons mec-3 Parker et al [11]
muscle unc-54 Wang et al [19]
DRPLAP::polyQ muscle unc-54 Yamanaka et al [18]
GFP::polyQ muscle unc-54 Saytal et al [14]
pan-neuronal rgef-1 Brignull et al [82]
α-synuclein pan-neuronal aex-3 Lakso et al [21]
dopaminergic neurons dat-1
dopaminergic neurons dat-1 Cao et al [22]
dopaminergic neurons dat-1 Kuwahara et al [23]
pan-neuronal unc-51 Kuwahara et al [25]
α-synuclein::GFP muscle unc-54 Hamamichi et al [26]
α-synuclein::YFP muscle unc-54 van Ham et al [27]
β-amyloid peptide muscle unc-54 Link [31]
inducibe muscle myo-3 Link et al [38]
inducible pan-neuronal snb-1 Wu et al [39]
tau pan-neuronal aex-3 Kraemer et al [50]
mechanosensory neurons mec-7 Miyasaka et al [57]
pan-neuronal rgef-1 Brandt et al [58]
SOD1 muscle myo-3 Oeda et al [60]
heat shock inducible hsp-16.2
pan-neuronal snb-1 Wang et al [61]
SOD1::YFP muscle unc-54 Gidalevitz et al [62]
LRRK2 pan-neuronal snb-1 Saha et al [63]
mouse prion protein muscle unc-54 Park and Li [64]Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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protein (CBP) and its associated histone acetyltransferase
activity [6,7]. Inhibition of histone deacetylase activity
can counter this effect and subsequently reduce Ht-polyQ
toxicity [8,9]. The ability to knock down specific gene
expression in C. elegans by a simple feeding RNA interfer-
ence procedure [10] allowed Bates et al to quickly assess
the roles of 8 specific histone deacetylases in Ht-polyQ.
Interestingly, knock down of one deacetylase (hda-3)
reduced polyQ toxicity, while knockdown of the others
increased toxicity as expected. Introduction of loss of
function mutations for hda-1, hda-4, and sir-2.1 similarly
enhanced Ht-polyQ toxicity.
A conceptually similar model for HD was developed by
Parker et al [11] using the mec-3 promoter to express an N-
terminal 57 residue fragment of huntingtin (with or with-
out expanded polyglutamine repeats) fused to Green Flu-
orescent Protein (Ht-polyQ::GFP). The mec-3 promoter is
active in 10 (non-essential) neurons, including the six
touch receptor cells. Ht-polyQ::GFP toxicity was assayed
by measuring touch responsivity in individual transgenic
worms. As observed in the osm-10 model, increasing the
number of polyglutamine repeats in the transgene led to
increased deficits in touch sensitivity. Transgene-induced
touch insensitivity was not associated with death of the
touch cells, but could be associated with visible morpho-
logical abnormalities in touch cell axons. This model was
subsequently used to demonstrate that over-expression of
the  sir-2.1  deacetylase could protect against Ht-
polyQ::GFP toxicity [12]. This result was extended by
demonstrating that resveratrol, a demonstrated activator
of sirtuin acetylases, could protect against Ht-polyQ toxic-
ity in both worm and neuronal culture models. Interest-
ingly, sir-2.1 or resveratrol protection in the C. elegans mec-
3/Ht-polyQ model was dependent on the FOXO tran-
scription factor daf-16, suggesting that this protection was
not due to reversal of Ht-polyQ effects on histone acetyla-
tion per se. The mec-3/Ht-polyQ:: model has also been
used to demonstrate a protective role for hipr-1, a
homolog of the HIP1 huntingtin-interacting protein,
against Ht-polyQ toxicity [13].
Perhaps a more general approach towards understanding
polyglutamine repeat toxicity was initiated by the Morim-
oto lab, which examined the effects of short (Q19) and
long (Q82) polyglutamine repeat lengths fused directly to
GFP and expressed in C. elegans body wall muscle cells
[14]. Expression of GFP::Q82 resulted in aggregate forma-
tion and induction of heat shock proteins. Subsequent
studies with a series of YFP-polyQ fusions demonstrated a
narrow threshold of polyQ repeat size (35-40) for induc-
tion of aggregation and toxicity [15]. Examination of
transgenic worms expressing threshold-level glutamine
repeats (Q40) demonstrated a strong age dependence for
aggregation as well as significant individual variability.
This model system was employed in an elegant series of
studies to demonstrate that formation of polyQ aggre-
gates generally disrupted protein homeostasis [16]. Intro-
duction of an aggregation-prone YFP::polyQ transgene
into a collection of temperature-sensitive missense muta-
tions was found to dramatically enhance the phenotypes
of these mutants, while conversely the presence of these
missense mutations was found to enhance the aggrega-
tion of YFP::polyQ. These studies are consistent with a
general "chaperone depletion" model that posits that
aggregating protein toxicity results from competition for
limited components of the protein homeostasis machin-
ery. Indeed, a large scale RNAi screen for modifiers of
YFP::polyQ aggregation identified a large set of genes
involved in protein folding or degradation that increased
polyQ aggregation when their expression was knocked
down [17].
Additional C. elegans polyQ models have been generated
with muscle-expressed polyglutamine repeats associated
with either 17 amino acid residues derived from the den-
tatorubural pallidoluysian atrophy protein (DRPLAP)
[18] or huntingtin exon 1 [19]. The former model has
been used to demonstrate protective effects of C. elegans
p97 homologs CDC-48.1 and CDC-48.2, while the latter
model was used to show ubiquilin protection against
polyQ toxicity. The muscle Ht-polyQ model has recently
been used to implicate mitochondrial fission/fusion in
huntingtin toxicity [20].
The studies described above illustrate the advantages (and
disadvantages) of C. elegans neurodegeneration model
systems, and the type of findings that can be made. The
ability to undertake unbiased forward genetic screens ena-
bled the identification of a novel gene involved in Ht-
polyQ toxicity (pqe-1). However, vertebrate homologs of
pqe-1 do not contain the relevant glutamine/proline-rich
portion of this protein, so the direct relevance to HD is
unclear. The optical transparency and short lifespan of C.
elegans  readily allowed the demonstration of an age-
dependence for polyQ aggregation, something that is dif-
ficult to do directly in other model systems. Similarly, the
existence of a large collection of characterized C. elegans
mutations enabled the important demonstration of
polyQ aggregation-dependent perturbation of protein
homeostasis. The technically simple feeding RNAi proto-
col has enabled a number of candidate genes (e.g., hda-1,
hda-4, sir-2.1, hipr-1, cdc-48.1,2 and dpr-1) to be impli-
cated in in vivo polyQ toxicity. As is the case in other
model systems, however, the use of different transgenic
constructs by different research groups does confound
making direct parallel between some studies. For exam-
ple, it is unclear if toxicity in the neuronal expression osm-
10/Ht-Q150 model is due to the disruption of proteinMolecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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homeostasis, or if the huntingtin sequences themselves
play an important role.
Models of α-synuclein toxicity
α-synuclein is a major component of Lewy bodies found
in dystrophic dopaminergic neurons in Parkinson's dis-
ease (PD), and α-synuclein mutations have been found to
be casual in a relatively small number of familial PD cases.
C. elegans models of synucleinopathy have been estab-
lished with human α-synuclein expression in either
dopaminergic neurons [21-23] or pan-neuronally
[21,23]. Lasko et al observed movement deficits in worms
with pan-neuronal expression of wild type or A53T α-
synuclein, while Kuwahara did not observe any pheno-
typic effects of pan-neuronal wild type, A30P, or A53T α-
synuclein expression. (These differences may be a result of
the specific promoters used in the transgene construc-
tions; Lasko et al used the aex-3 promoter, while Kuwa-
hara et al used the unc-51 promoter). However, all three
groups have reported loss of either dopaminergic neuron
cell bodies or dendrites when α-synuclein expression is
driven by the dopaminergic-specific dat-1  promoter.
Kuwahara et al also observed preferential neuronal dys-
function in worms expressing mutant α-synuclein (A53T
or A30P) relative to wild type, measuring either dendritic
loss or deficits in behaviors (slowing upon food sensa-
tion) known to be dopamine-dependent. The dat-1/wt α-
synuclein model of Cao et al was used to demonstrate the
protective effects of the chaperone protein torsin A [22]
and Rab1, a protein believed to function in Golgi vesicular
trafficking [24]. The pan-neuronal α-synuclein model of
Kuwahara et al has been used in a large-scale feeding RNAi
screen to identify enhancers of α-synuclein toxicity, lead-
ing to the identification of a number of genes (e.g., apa-2,
aps-2, eps-8 and rab-7) involved in the endocytic pathway
[25]. Studies of C. elegans α-synuclein models have thus
strongly supported the link between α-synuclein toxicity
and intracellular (synaptic?) vesicle trafficking.
C. elegans models have also been constructed to look for
genes specifically influencing α-synuclein aggregation,
following the approach initially developed for polyQ-
induced aggregation [17]. The Caldwell and Nollen
groups both demonstrated that α-synuclein::GFP (or YFP)
fusion protein expressed in C. elegans muscle cells leads to
the formation of visible fluorescent aggregates, as previ-
ously observed for GFP::polyQ ([26,27]. Hamamichi et al
initially tested 868 "hypothesis based" RNAi clones for
enhancement of α-syn::GFP aggregation. (This screen was
sensitized by co-expression of TOR-2 to reduce initial
aggregation levels.) Twenty genes were ultimately identi-
fied that increased α-syn::GFP aggregation when their
expression was knocked down early in development by
feeding RNAi. Seven of these genes were tested for effects
on  α-synuclein toxicity (not necessarily equivalent to
aggregation) by transgenic overexpression in the dat-1/α-
synuclein model; five were found to partially suppress
dopaminergic neuron loss. Interestingly, these validated
aggregation/toxicity enhancer genes included the vacuolar
assembly/sorting protein vps-41  and the autophagy-
related atgr-7. van Ham et al similarly screened for genes
that increased α-syn::YFP aggregation after RNAi knock-
down, in this case using the "whole genome" Ahringer
feeding RNAi library, which contains ~15,000 clones
(~85% of the genome represented). 80 genes were identi-
fied, with an over-representation of lipid- and vesicle-
associated genes. For three of these genes (sir-2.1, lagr-1,
and  ymel-1) suppression of α-syn::YFP aggregation was
independently confirmed using genetic loss-of-function
mutations.
Perhaps the most interesting result from these two large-
scale screens is that essentially no overlap was identified
between genes that suppressed GFP::polyQ and α-
syn::GFP aggregation. This observation is consistent with
results from yeast studies and supports the view that
aggregation of different disease-associated proteins is not
equivalent. However, it should be pointed out that there
is also no overlap in the genes identified in the Hamam-
ichi et al and van Ham et al studies. This lack of overlap
could be the result of technical differences between the
two screens, and in fact non-congruence between similar
C. elegans RNAi screens is not uncommon (e.g., [28,29]).
Large scale RNAi screens in C. elegans appear to have an
inherent variability, and thus negative results from these
screens should be interpreted cautiously.
Models of β amyloid peptide toxicity
The β-amyloid peptide (Aβ) is a primary component of
senile plaques found in the brains of Alzheimer's disease
(AD) patients, and the existence of mutations in the gene
encoding Aβ (Amyloid Precursor Protein, APP) in a subset
of familial AD cases argues for a causal role for this pep-
tide in this disease. Aβ has also been found to accumulate
in muscles of patients with Inclusion Body Myositis, a
debilitating myopathy [30]. Initial attempts to use C. ele-
gans to understand Aβ toxicity employed the unc-54 pro-
moter to constitutively express a signal peptide::Aβ
minigene in body wall muscle [31]. Transgenically-
expressed Aβ was found to accumulate intracellularly in
muscle cells, and result in an age-dependent paralysis
phenotype. This intracellular Aβ was able to form amyloid
dye-reactive deposits with a fibrillar ultrastructure (i.e.,
amyloid deposits) [32]. Single amino acid substitutions
(e.g., Leu17Pro) were identified that blocked amyloid for-
mation in this model but did not reduce toxicity, suggest-
ing that amyloid itself is not the toxic species [33]. The
HSP-16 family of small heat-shock proteins was found to
be induced by and co-immunoprecipitate with Aβ in this
model [34], and ectopic expression of HSP-16 could sup-Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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press Aβ toxicity [35]. Cohen et al [36] used the unc-54/
signal peptide::Aβ 1-42 model to investigate the roles of
two important modulators of C. elegans lifespan, the insu-
lin growth factor 1-like signaling (ILLS) pathway and heat
shock factor (HSF), in Aβ toxicity. RNAi knockdown of
either daf-16 (the FOXO transcription factor that controls
gene expression downstream of ILS) or hsf-1 enhanced Aβ
toxicity, while activation of DAF-16 (via RNAi knockdown
of daf-2, a negative regulator of daf-16) suppressed toxic-
ity. Bacterial deprivation, a form of dietary restriction that
extends lifespan in C. elegans, has also been found to
reduce Aβ (and polyQ) toxicity in a HSF-dependent man-
ner [37].
Overall, the results of studies with worms with constitu-
tive muscle expression of either Aβ or YFP::polyQ are sim-
ilar, and suggest that in both cases the observed toxicity
primarily results from a general perturbation of protein
homeostasis (proteostasis). Interestingly, neither DAF-16
activation nor bacterial deprivation was observed to
reduce the overall accumulation of Aβ, despite being pro-
tective. These results suggest that upregulation of the
chaperone/protein folding machinery is protective either
because this blocks the formation of some specific toxic
form of Aβ (supported by the results of Cohen et al, who
found changes in the aggregation state of Aβ correlating
with toxicity) and/or because this compensates for a gen-
eral depletion of chaperone capacity by deposition of Aβ
aggregates. It is an open question whether the unc-54/sig-
nal peptide::Aβ 1-42 model is directly relevant to Alzhe-
imer's disease, as the levels of intraneuronal Aβ
accumulation in the brain are unlikely to reach the intra-
cellular Aβ levels generated in this model. However,
results from this model may be generally instructive in
that they suggest that the age-dependence of AD on other
neurodegenerative conditions may stem from age-
dependent loss of the ability to maintain cellular protein
homeostasis. It should be noted that this model may be
more directly relevant to inclusion Body Myositis, given
the parallels of intramuscular Aβ accumulation.
Transgenic worms have also been engineered to inducibly
express Aβ upon temperature upshift, either in muscle
[38] or pan-neuronally [39]. This temperature inducibility
was engineered by using transgene constructs with abnor-
mally long 3' untranslated regions, resulting in transgenic
transcripts that are subject to degradation by the mRNA
surveillance system. Introduction of these transgenes into
worms containing a temperature-sensitive mutation in a
gene essential for mRNA surveillance (smg-1) resulted in
strains that had a ~5-fold increase in transgenic transcripts
when shifted from the permissive (16°C) to non-permis-
sive (23°C) conditions [37]. An advantage of this system
is that, at least for engineered muscle expression, trans-
genic strains have been constructed that have wild type
movement at the permissive temperature but become rap-
idly (~24 hr) and uniformly paralyzed upon temperature
upshift. The reproducible phenotype of the myo-3/signal
peptide::Aβ 1-42/long 3' UTR model has allowed straight-
forward quantification of the effects of treatments on Aβ
toxicity, and has been used to demonstrate the protective
effects of specific gingkolides [39]. This inducible model
has also been used to demonstrate a role for autophagy in
countering Aβ toxicity [40]. Microarray studies with this
model identified AIP-1, a conserved protein thought to be
a positive regulator of proteasome function [41,42], as an
Aβ-induced protein that protects against toxicity by reduc-
ing Aβ accumulation [43]. Interestingly, a human
homolog of AIP-1, AIRAPL, also reduces toxicity when co-
expressed with Aβ.
Transgenic worms with pan-neuronal expression (signal
peptide::Aβ driven by the snb-1 promoter) were found to
have intraneuronal accumulation of Aβ [44] but relatively
mild phenotypes, including altered chemotaxis to benzal-
dehyde and hypersensitivity to exogenous serotonin [39].
It is unclear if the apparent differences in the severity of
phenotypes resulting from muscle or neuronal expression
reflect differences in the manner by which C. elegans mus-
cle and neuronal cells respond to Aβ, or simply quantita-
tive differences in the effective expression levels resulting
from the use of different promoters. McColl et al [45] have
recently demonstrated by mass spectrometry that in the
unc-54/signal peptide::Aβ 1-42 constitutive model the
species of Aβ that accumulates is actually Aβ 3-42, likely
due to signal peptidase cleavage after Ala2  of the Aβ
sequence. As the inducible models utilize the same signal
peptide::Aβ minigene, it is likely that all of these models
produce the truncated Aβ 3-42. The 3-42 form of Aβ is
readily found in senile plaques, where the N-terminal
glutamate residue is often converted to pyroglutamate
[46]. However, McColl and colleagues did not detect
pyroglutamate-modified Aβ in the transgenic worm
model.
Tauopathy models
Alzheimer's disease, as well as Pick's disease and some
forms of frontotemporal lobar dementia (FTLD), are asso-
ciated with intraneuronal accumulation of neurofibrillary
tangles (NFTs) composed of the microtubule binding pro-
tein tau. Mutations in tau have been demonstrated to
underlie familial FTLD linked to chromosome 17 (FTLD-
17) [47-49], causally linking tau to some forms of neuro-
degeneration. Kraemer et al established a C. elegans tauop-
athy model by expressing wild type or FTLD-17-mutant
tau pan-neuronally using the aex-3 promoter [50]. This
model system replicated key observations of the human
disease: accumulation of insoluble, phosphorylated tau,
evidence of age-dependent neuronal degeneration and
loss, a clear organismal phenotype (uncoordinated move-Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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ment), and greater toxicity in worms expressing FTLD-17-
mutant tau (V337M and P301L) than in worms expressing
wild type tau. The uncoordinated phenotype of the aex-3/
tau worms has been used for both classic forward genetic
and RNAi-based reverse genetic screens, resulting in inter-
esting (and perhaps unexpected) findings. Genetic screens
based on chemical mutagenesis and positional cloning
have identified two genes, sut-1 [51] and sut-2 [52], whose
loss of function suppresses the tau-induced uncoordi-
nated phenotype. sut-1 encodes a nematode-specific pro-
tein that binds Sm proteins and SmY, a small nematode-
specific RNA of unknown function [53]. However, Krae-
mer and Schellenberg were able to use yeast two-hybrid
and genetic studies to demonstrate that sut-1  interacts
with UNC-34, a member of the conserved Ena/VASP pro-
tein family. They speculated that this interaction may
modulate actin dynamics and thereby ultimately suppress
tau pathology. sut-2  is a zinc finger-containing protein
homologous to yeast Nab2 and human ZC3H14. Nab2
has demonstrated roles in the nuclear export of mRNA
[54], and both Nab2 and ZC3H14 have been shown to
bind polyadenosine sequences [55]. Guthrie et al also
found by two yeast hybrid studies that C. elegans protein
ZYG-12, and its human homolog HOOK2, can interact
with SUT-2. Given that HOOK2 is a component of aggre-
somes, these authors suggested that sut-2 suppression of
tau pathology could involve either aggresome effects on
tau accumulation or, conversely, tau effects on proper
aggresome formation.
The aex-3/tau V337M model was used as the basis for a full
genome feeding RNAi screen (16,757 RNAi clones
assayed), looking for modifiers of the tau-induced unco-
ordinated phenotype [56]. Although no suppressor RNAi
clones were found, 60 genes were eventually identified
that specifically enhanced the tau-induced phenotype
when their expression was knocked down by RNAi. These
genes encoded proteins with a surprising range of func-
tions, including phosphorylation, chaperone activity,
neurotransmission and signaling, RNA processing, and
various enzymatic functions. Seven of these genes (sir-2.3,
vap-1, lin-44, aex-1, acr-14, pxn-1, and mut-14) were inde-
pendently tested by introducing genetic loss-of-function
mutations into the aex-3/tau V337M background; in all
cases the enhancement of the uncoordinated phenotype
was recapitulated. The range of identified enhancer genes
may reflect a multitude of steps by which neurons nor-
mally counter either toxic protein accumulation (e.g.,
altering tau modification, aggregation, or degradation) or
its downstream consequences. Alternatively, the apparent
interaction of these genes with tau pathology could result
from a rather indirect synergism in which a reduction of
gene function that normally results in a phenotypically
undetectable compromise of neuronal function (e.g.,
reduction of acr-14, one of the many acetylcholine recep-
tors in C. elegans) nevertheless significantly exacerbates
tau pathology in a perhaps additive fashion. In any case,
the interacting genes identified by both forward and
reverse genetic approaches with this model suggest poten-
tially novel mechanisms of tau pathology that warrant
investigation.
Tau pathology has also been engineered in C. elegans by
expressing wild type and FTLD-17-mutant tau specifically
in touch neurons, using the mec-7 promoter [57]. Trans-
genic expression of tau in the touch neurons resulted in an
age-dependent loss of touch sensitivity, again with FTLD-
17-mutant tau (P301L and R406W) showing enhanced tox-
icity. This model was used to test the effects of HSP70
overexpression (mild suppression of mutant tau toxicity),
GSK-3 overexpression (mild enhancement of tau toxic-
ity), or genetic blockage of apoptosis (no effect on tau tox-
icity). Brandt et al [58] examined the role of
phosphorylation in tau toxicity by using the rgef-1 pro-
moter to engineer pan-neuronal expression of wild type,
pseudophosphorylated (10 specific kinase target serine
residues changed to glutamate), or phosphorylation-
resistant (10 specific kinase target serine residues changed
to alanine) tau. Both wild type and glutamate-substituted
tau were observed to have similar age-dependent uncoor-
dinated phenotypes, although worms expressing the
glutamate-substituted tau had higher levels of abnormal
motorneurons. (The alanine-substituted tau also induced
an uncoordinated phenotype, although this was hard to
interpret because transgenic lines expressing this modified
tau all had significantly higher levels of tau expression.)
Neuronal death was not observed in either the mec-7/tau
or rgef-1/tau models. However, in both models neuronal
outgrowth abnormalities were observed. While this could
be indicative of developmental effects of tau expression
on axon pathfinding, similar abnormal outgrowth has
been observed as a result of regeneration of broken axons
[59], suggesting the alternative possibility that tau expres-
sion results in fragile axonal processes more susceptible to
movement-induced breakage.
Other transgenic models
Mutations in superoxide dismutase (SOD1) are the most
common known cause of familial Amyotrophic Lateral
Sclerosis (fALS). Oeda et al [60] generated the first C. ele-
gans model of SOD1 toxicity by expressing wild type or
fALS mutant SOD1 (A4V, G37R, or G93A), using either the
muscle-specific myo-3 promoter or the heat-shock induci-
ble hsp-16.2 promoter. While these transgenic worms were
not reported to have discernable phenotypes under stand-
ard conditions, worms expressing the fALS mutant SOD1
were found to be preferentially sensitive to paraquat.
Wang et al [61] engineered pan-neuronal SOD1 expres-
sion using the snb-1 (synaptobrevin) promoter, expressing
both wild type and G85R fALS mutant SOD1. ExpressionMolecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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of SOD1 G85R (fused to YFP or unfused), but not wild
type SOD1, resulted in a clear age-dependent inhibition
of locomotion. Transgenic worms expressing G85R
SOD1::YFP also had visible fluorescent aggregates in neu-
rons, allowing a full genome feeding RNAi screen in a sen-
sitized eri-1; lin-15b genetic background. As observed in
the RNAi screens of the aex-3/tau model, both expected
(e.g., chaperone-related genes such as hsf-1) and unex-
pected (topoisomerase gene top-1, TGF β component dbl-
1) were recovered as aggregation/toxicity enhancers. (One
aggregation/toxicity suppressor was also identified but
not described in this study.) Transgenic worms expressing
SOD1::YFP fusions have also been constructed by Gida-
levitz et al [62], who used the unc-54 muscle-specific pro-
moter to express wild type and G85R, G93A, and truncated
(127X) fALS mutant SOD1. As reported by Wang et al, fALS
SOD1::YFP, but not wild type, formed visible aggregates.
While transgenic worms expressing fALS mutant
SOD1::YFP had relatively mild phenotypes, introduction
of temperature-sensitive missense mutations (the same
mutant alleles that are enhanced by YFP::polyQ aggrega-
tion) strongly exacerbated SOD1::YFP toxicity in an fALS
mutant-specific manner. This result nicely complements
the previous YFP::polyQ study by the Morimoto group,
and supports the idea that misfolded proteins (i.e., desta-
bilized missense mutant proteins and fALS mutant
SOD1) compete for limiting protein homeostasis machin-
ery.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the
most common known cause of familial Parkinson's dis-
ease (fPD). LRRK2 is highly conserved, and C. elegans con-
tains a clear ortholog, lrk-1. Saha et al [63] have recently
shown that knockdown of lrk-1 sensitizes worms to the
mitochondrial toxic rotenone, while pan-neuronal
expression of wild type human or G2019S fPD LRRK2
(driven by the snb-1 promoter) protects against rotenone
toxicity. However, transgenic LRRK2 expression also led to
a preferential loss of dopaminergic neurons, with G2019S
fPD LRRK2 being measurably more toxic than wild type
LRRK2. This model should be amenable to the
approaches previously used in the transgenic α-synuclein
models.
Pathological forms of the prion protein (PrP) are believed
to be the cause of fatal spongiform encephalies, including
Creutzfeldt-Jakob disease (CJD), kuru, and Bovine Spong-
iform Encephaly (BSE). There is a single report describing
the expression of mouse prion protein (residues 23-231)
in  C. elegans [64]. Muscle expression of a MoPrP(23-
231)::CFP fusion protein (but not the CFP-only control)
was found to induce visible fluorescent aggregates and a
variable "Dumpy" phenotype, associated with poor loco-
motion and sarcomere disruption. Parallel expression of
PrP expressing the P102L mutation associated with Gerst-
mann-Straussler-Scheinker disease resulted in a more
severe movement deficit, while co-expression of PrP con-
taining a dominant negative mutation (MoPrP
Q167R::YFP) with MoPrP::CFP reduced apparent toxicity.
However, proteinase K-resistant MoPrP could not be
detected in transgenic worms, suggesting that the infec-
tious scrapie form of PrP (PrPsc) was not being formed.
Given the lack of PrPsc formation and the fact that the
transgenic constructs lack the N-terminal lipidation
sequences of PrP likely important in pathology, it is
unclear if this model is directly relevant to infectious
prion diseases or is instead more akin to the general pro-
tein aggregation toxicity models.
So what have we learned from C. elegans 
transgenic models?
While some of the findings from these models have been
robustly demonstrated in other systems (e.g., the role of
histone deacetylases in Ht::polyQ toxicity), some are
clearly novel and/or have potentially broad significance to
neurodegeneration. The studies of Gidalevitz et al [16]
demonstrating how polyQ deposition alters the folding
and function of other proteins provides the first clear
experimental support for the hypothesis that aggregation-
induced chaperone depletion (e.g., as suggested to explain
the toxicity of ALS-mutant SOD1, [65]) can cause cellular
dysfunction. The studies with worm α-synuclein models
have strongly implicated vesicular function in α-synuclein
toxicity [24-26]. Studies with treatments that modulate C.
elegans lifespan have suggested why age is the primary risk
factor for most neurodegenerative diseases [36,37]. The
studies of Kraemer and colleagues in particular have iden-
tified a number of unexpected genes with a putative role
in tau pathology [51,52,56], explicitly demonstrating the
advantages of C. elegans models that are amenable to
unbiased experimental approaches.
Future prospects
New C. elegans neurodegeneration models are likely to be
developed in the near future, taking advantage of both
technical advantages (directed single copy transgene
insertions, tetracycline-induced transgene expression),
and the identification of new neurodegeneration-associ-
ated genes (e.g., TDP-43). Existing approaches have cer-
tainly not been exhausted, as genetic modifier screens
have not been done to saturation, and some published
large scale RNAi screens could still be expanded to full-
genome screens. Clearly, some of the C. elegans findings
still await validation in mammalian models. This is partic-
ularly important with respect to unexpected modifier
genes identified in RNAi screens, given the possibility that
these genes could be an artifactual result of worm-specific
biology or the highly engineered nature of the model sys-
tem. An important question that has not been rigorously
addressed is to what degree underlying pathological proc-Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
Page 9 of 13
(page number not for citation purposes)
esses overlap between the various neurodegeneration
models. While some studies point to potential overlap of
pathological processes (e.g., the common demonstration
that loss of hsf-1 function enhances aggregation/toxicity),
it remains to be determined if any suppressors in specific
models also have effects in other neurodegeneration mod-
els (e.g., do sut-1 or sut-2 suppress α-synuclein or polyQ
toxicity?). Technical improvements in C. elegans handling
(e.g., the COPAS worm sorter and microfluidic worm
manipulation) will also likely enable more efficient use of
transgenic worm models in compound screening.
C. elegans neurodegeneration model check list
A sufficient number of studies have now been undertaken
using transgenic C. elegans neurodegeneration models
that a set of considerations can be established as to what
is needed to establish an informative model.
1) Choice of expression system
Expression of a human disease-associated protein
involves the construction of a chimeric transgene employ-
ing a C. elegans promoter and a human cDNA. Promoters
used are typically either pan-neuronal (e.g., unc-119, snb-
1, aex-3, rgef-1, etc.) or targeted to specific neuronal sub-
types (e.g., mec-7; mechanosensory neurons, osm-10;
chemosensory neurons; dat-1; dopaminergic neurons,
etc.). Body wall muscle-specific promoters (unc-54 and
myo-3), which give strong and highly specific expression,
have also been used. Promoter choice depends upon both
technical considerations and specific questions being
addressed. Many neurodegeneration-associated proteins
are widely expressed (e.g., Abeta, tau, α-synuclein), and
thus pan-neuronal promoters may be logical choices for
these types of proteins. An advantage to this approach is
that if pan-neuronal expression leads to toxicity in specific
neuronal sub-populations (e.g., pan-neuronal expression
of α-synuclein leading to specific dopaminergic neurotox-
icity), it strengthens the validity of the model. However, if
pan-neuronal expression of a disease-associated protein is
strongly toxic, it may be impossible to recover transgenic
strains in the first place. In these instances, targeting
expression to non-essential neuronal sub-populations
such as chemosensory neurons may be required.
Unfortunately, expression systems equivalent to the Gal4/
UAS or tetracycline-induction systems developed for Dro-
sophila have not yet been described for C. elegans
(although this will likely change in the near future, R. Bau-
meister, personal communication). Thus, cell- or tissue-
specific transgene expression must be individually engi-
neered, and conditional expression has been limited to
engineering heat-shock-inducible transgenes (which can
be confounded by the general effects of heat shock) or the
use of a temperature-sensitive mRNA surveillance system
that leads to temperature-dependent levels of transgene
expression [38], but does not allow on/off regulation.
2) Choice of expressed proteins
Interpretation of the effects of heterologous protein expres-
sion is completely dependent upon parallel development of
the appropriate transgenic controls. The preferable situa-
tion is to express in parallel wild type and familial disease
mutant forms of a disease protein (e.g., as is available for
tau, α-synuclein, SOD1, etc). Enhanced toxicity of the dis-
ease mutant forms provides support for the relevance of
the transgenic model. Alternatively, it may be possible to
generate disease protein variants predicted to be non-toxic
(e.g., making a kinase-dead version of a disease-associated
protein kinase). Demonstrating that a single amino acid
change in a disease protein renders it non-toxic strongly
argues against "non-specific over-expression" interpreta-
tions of transgene toxicity. As many (if not all) neurode-
generation-associated proteins are aggregation-prone, it is
also possible to control for general aggregation toxicity by
parallel expression of a "generic" aggregating protein such
as GFP::degron [66].
(It should be noted that comparison of transgenic animals
expressing "more" and "less" toxic versions of disease-
associated proteins is not routinely done with mouse
transgenic models, as transgenic mice are typically com-
pared to their non-transgenic siblings. However, given the
relative ease of establishing transgenic C. elegans strains,
there is no rationale for not generating parallel control
transgenic strains.)
Transgenically expressed disease proteins can conceivably
be expressed with epitope (e.g., FLAG or myc) or fluores-
cent protein tags, although this is often unnecessary and
potentially risks altering transgenic protein activities. An
advantage of expressing human genes in C. elegans is that
there is generally little cross-reactivity between specific
antibodies for the human protein and worm proteins, and
therefore immunoblots and/or immunohistochemistry
can readily be used to follow the expression of the trans-
genic protein if appropriate antibodies exist. Protein
fusions to GFP or other fluorescent can be very useful for
rapidly establishing transgene expression and for deter-
mining the sub-cellular distribution of the transgenic pro-
tein.
3) Construction of transgenic worms
There are currently three general approaches to establish-
ing transgenic C. elegans strains. Transgenic strains with
multicopy extrachromosomal arrays can readily be gener-
ated by gonad microinjection [67]. Irradiation and screen-
ing of these extrachromosomal transgenic strains can be
used to subsequently derive completely stable, chromo-
somally integrated transgenic lines. Neither transgene
copy number nor chromosomal insertion site can be con-
trolled using this method. Transgenic strains can also be
generated by ballistic transformation [68,69], which can
directly generate single- or low copy number- transgeneMolecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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insertions into the chromosome. The site of chromosomal
insertion is also random in this case. The recently devel-
oped Mos1-mediated single copy insertion technique
(MosSCI) employs transposon excision and repair to
introduce single copy transgene insertions in specific
chromosomal locations [70]. This approach has great
potential to generate reproducible transgenic models that
will simplify comparisons of independent transgenic
strains (e.g., strains expressing different disease mutant
forms of a neurodegeneration-associated protein) and
avoid the complications associated with high-copy trans-
genic arrays (high expression, germline silencing, poten-
tial genetic instability, etc).
Construction of C. elegans transgenic strains generally
requires co-introduction of a marker transgene that ena-
bles identification of transgenic worms independent of
the (usually unknown) effects of the experimental dis-
ease-associated transgene. For transgenic strains generated
by the muticopy array approach, the marker transgene can
be easily co-introduced by adding marker transgene plas-
mid DNA to the injection mix, as all injected DNA is typ-
ically assembled into the transgenic array. A plasmid
encoding dominant mutant collagen [rol-6(su1006)] was
commonly used as a marker transgene in early transgenic
constructs [67], as introduction of this marker leads to an
easily recognized "Roller" phenotype that can be seen
with a standard dissecting microscope. GFP-expressing
constructs (e.g. myo-2 promoter::GFP) are also routinely
used as marker transgenes. An alternative approach is to
use a plasmid that encodes a transgene that can rescue a
chromosomal mutant, resulting in transgenic worms with
wild type phenotypes against a background of mutant
non-transgenic worms. Plasmids encoding wild type LIN-
15 (rescuing a multivulval phenotype caused by recessive
lin-15 mutations) or DPY-20 (rescuing a "Dumpy" pheno-
type caused by recessive dpy-20  mutations) have been
used in this approach. Although this approach can sim-
plify identification of transgenic worms, it does require
using mutant backgrounds and has the potential con-
found of partial rescue of the chromosomal mutation
complicating characterization of the experimental trans-
gene phenotypes.
For ballistic- or MosSCI-mediated transformation, the
marker transgene must be incorporated into the same
plasmid as the experimental transgene. Expression of wild
type UNC-119 protein has most commonly been used as
the marker in these transformation techniques, with unc-
119  mutant worms as the recipient. This approach is
advantageous not only because the transgenic rescue of
the severely uncoordinated unc-119 phenotype is easily
seen, but because this rescue can be selected for under
appropriate conditions. unc-119  mutant worms cannot
enter the starvation-resistant dauer larval stage, and thus
starvation of populations of unc-119 mutant worms sub-
jected to ballistic transformation strongly enriches for
transformed worms.
4) Demonstration of transgene expression
The first step after establishment of a transgenic strain is
demonstration of expression of the expected transgenic
protein, typically done by immunoblot and/or immuno-
histochemistry. C. elegans adult worms contain ~0.4 μg of
total protein, so 50-100 worms are sufficient material for
one SDS-PAGE lane. Detection of transgenic proteins by
immunoblot can be more difficult if expression is limited
to small numbers of cells (e.g., the 8 dopaminergic neu-
rons in C. elegans). Multiple protocols have been estab-
lished for C. elegans whole mount immunohistochemistry
[71], which can be used to establish transgene expression
even if limited to a single cell in the worm. Transgenic pro-
teins can of course be fused with GFP or other fluorescent
proteins, which allows direct visualization of transgene
expression at the risk of altering transgenic protein func-
tion.
5) Establishment of transgene-associated phenotypes
Genetic (or chemical) screens require phenotypes, and
thus transgenic C. elegans models with weak or non-exist-
ent phenotypes are less likely to be informative. In some
cases, transgenic expression of disease-associated proteins
can lead to strong, easily discernable phenotypes, such as
uncoordinated movement in worms with transgenic neu-
ronal expression of tau [50] or paralysis in worms with
muscle expression of Aβ [31]. However, even weak trans-
genic phenotypes can be useful, as they can be effectively
used for enhancer screens (e.g., [25]).
Compound screening using C. elegans models
C. elegans neurodegeneration models have been used to
test the effects of individual drugs (e.g., resveratrol in a
polyQ model, [12]; acetaminophen in multiple PD mod-
els, [72]) or relatively small collections of compounds
(e.g., subcomponents of Gingko biloba extracts in Aβ tox-
icity models, [39], candidate Huntington's drugs in a
polyQ model, [73]). Although large numbers of replicate
C. elegans populations can be readily grown in small vol-
umes (e.g., microtiter wells), a previous hindrance in
moving from low- to high-throughput screenings (HTS)
was the requirement for manual manipulation and phe-
notypic scoring of worms. Recent technical advances have
now overcome many of the practical limitations in using
C. elegans models for HTS, most prominently the develop-
ment of the Complex Object Parametric Analyzer and
Sorter (a.k.a. the COPAS "worm sorter", [74]). This instru-
ment can rapidly sort individual worms on the basis of
length, optical density, and fluorescence, and can be used
to automate both manipulation and scoring. Burns et al
[75] demonstrated how this technology could be incorpo-Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
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rated with a high-throughput digital imager and data
management software for precisely scoring phenotype.
This protocol was used by Kwok et al [76] to effectively
screen four libraries comprised of 14,100 small mole-
cules, which resulted in their discovery of a new L-type cal-
cium channel antagonist. The COPAS instrument has
recently been used for high-throughput neurotoxin
screening [77], suggesting that this instrument should be
equally applicable for screening for neuroprotective com-
pounds in various neurodegeneration models.
For some relevant phenotypes, such as axonal regenera-
tion after microsurgery [78] or maintenance of motorneu-
ron synapses, subcellular observations are required.
Techniques are currently being developed that may allow
these challenging measurements to be automated, thereby
further expanding HTS possibilities. In 2007 the Yanik
group at MIT introduced a series of microfluidic devices,
otherwise known as lab-on-chip technology, applicable
for manipulating C. elegans [79]. Microfluidic devices
maneuver fluids and specimens on a sub-millimeter scale
via the use of layered control channels and valves. Given
the size of a C. elegans adult (~1 mM in length and 0.1 mM
in diameter), and that they are able to live out their 2-3
week lifespan suspended in liquid media, worms are an
ideal animal model for this technology. These microflu-
idic devices can be configured with 3-dimensional imag-
ing that allows for subcellular resolution. Additional key
components of these devices are the manner with which
immobilization of worms is achieved as well as the capa-
bility of continuous recirculation. A worm is captured by
way of a suction channel, which restricts its movement
and positions the worm in a linear fashion providing for
optimal imaging. Based upon its phenotype, the animal is
then either discarded or collected in a separate chamber
through a series to flow valves controls. In 2008, the Hang
Lu group demonstrated that integrating this lab-on-chip
technology and automated multiparametric analysis
could effectively identify and sort worms according to cel-
lular and subcellular phenotypes with 95% accuracy [80].
This technology has also facilitated procedures such as
those used in the in vivo ultrafast laser nanosurgery study
conducted by Ben-Yakar and Bourgeois [81]. By integrat-
ing lab-on-chip technology and femtosecond laser nano-
surgery they were able to increase the level of precision
and speed with which cellular and subcellular laser abla-
tions can be performed, suggesting the feasibility of large-
scale in vivo neural degeneration and regeneration studies.
Despite the technical advances relative to HTS in C. ele-
gans, biological considerations may still be the most
important factor in the potential usefulness of C. elegans
neurodegeneration models for drug identification. The C.
elegans cuticle is impermeant to many compounds that
readily diffuse into tissue culture cells, and thus com-
pound entry may require ingestion along with the stand-
ard E. coli food source. For a given compound, there is
currently no way to predict what final tissue concentration
will result from a given external compound dose, so dose/
responses need to be tested empirically. It can be argued
that the major advantage of compound screening in C. ele-
gans  is also the major disadvantage: protective com-
pounds can be identified without any assumptions about
neurotoxic mechanisms, however, when protective com-
pounds are identified, the molecular mechanism of pro-
tection may be unknown. This ignorance can be a major
hurdle in further drug development, as it limits both com-
pound optimization and predictions about possible side
effects. Nevertheless, investigations of protective com-
pounds can be a powerful approach to ultimately under-
standing the molecular mechanisms of
neurodegeneration.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DT and CDL both contributed to the writing of this man-
uscript and approve of the final submitted text.
Acknowledgements
The authors would like to thank Gin Fonte for the careful reading of this 
manuscript. CDL is supported by the NIH (grants R01 AG012423 and R01 
NS063964) and a Zenith Award from the Alzheimer's Association.
References
1. Kourtis N, Tavernarakis N: Non-developmentally programmed
cell death in Caenorhabditis elegans.  Semin Cancer Biol 2007,
17:122-33.
2. Ramot D, MacInnis BL, Goodman MB: Bidirectional temperature-
sensing by a single thermosensory neuron in C. elegans.  Nat
Neurosci 2008, 11:908-15.
3. Faber PW, Alter JR, MacDonald ME, Hart AC: Polyglutamine-
mediated dysfunction and apoptotic death of a Caenorhabdi-
tis elegans sensory neuron.  Proc Natl Acad Sci USA 1999,
96:179-84.
4. Faber PW, Voisine C, King DC, Bates EA, Hart AC: Glutamine/pro-
line-rich PQE-1 proteins protect Caenorhabditis elegans neu-
rons from huntingtin polyglutamine neurotoxicity.  Proc Natl
Acad Sci USA 2002, 99:17131-6.
5. Bates EA, Victor M, Jones AK, Shi Y, Hart AC: Differential contri-
butions of Caenorhabditis elegans histone deacetylases to
huntingtin polyglutamine toxicity.  J Neurosci 2006, 26:2830-8.
6. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J,
Merry D, Chai Y, Paulson H, Sobue G, Fischbeck KH: CREB-binding
protein sequestration by expanded polyglutamine.  Hum Mol
Genet 2000, 9:2197-202.
7. Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB: Cell death trig-
gered by polyglutamine-expanded huntingtin in a neuronal
cell line is associated with degradation of CREB-binding pro-
tein.  Hum Mol Genet 2003, 12:1-12.
8. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL,
Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Hous-
man DE, Jackson GR, Marsh JL, Thompson LM: Histone deacety-
lase inhibitors arrest polyglutamine-dependent
neurodegeneration in Drosophila.  Nature 2001, 413:739-43.
9. McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck
KH:  Histone deacetylase inhibitors reduce polyglutamine
toxicity.  Proc Natl Acad Sci USA 2001, 98:15179-84.Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
Page 12 of 13
(page number not for citation purposes)
10. Timmons L, Fire A: Specific interference by ingested dsRNA.
Nature 1998, 395:854.
11. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C:
Expanded polyglutamines in Caenorhabditis elegans cause
axonal abnormalities and severe dysfunction of PLM mech-
anosensory neurons without cell death.  Proc Natl Acad Sci USA
2001, 98:13318-23.
12. Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C,
Catoire H, Neri C: Resveratrol rescues mutant polyglutamine
cytotoxicity in nematode and mammalian neurons.  Nat Genet
2005, 37:349-50.
13. Parker JA, Metzler M, Georgiou J, Mage M, Roder JC, Rose AM, Hay-
den MR, Neri C: Huntingtin-interacting protein 1 influences
worm and mouse presynaptic function and protects
Caenorhabditis elegans neurons against mutant poly-
glutamine toxicity.  J Neurosci 2007, 27:11056-64.
14. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer
JM, Morimoto RI: Polyglutamine aggregates alter protein fold-
ing homeostasis in Caenorhabditis elegans.  Proc Natl Acad Sci
USA 2000, 97:5750-5.
15. Morley JF, Brignull HR, Weyers JJ, Morimoto RI: The threshold for
polyglutamine-expansion protein aggregation and cellular
toxicity is dynamic and influenced by aging in Caenorhabditis
elegans.  Proc Natl Acad Sci USA 2002, 99:10417-22.
16. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI: Progres-
sive disruption of cellular protein folding in models of poly-
glutamine diseases.  Science 2006, 311:1471-4.
17. Nollen EA, Garcia SM, van Haaften G, Kim S, Chavez A, Morimoto RI,
Plasterk RH: Genome-wide RNA interference screen identi-
fies previously undescribed regulators of polyglutamine
aggregation.  Proc Natl Acad Sci USA 2004, 101:6403-8.
18. Yamanaka K, Okubo Y, Suzaki T, Ogura T: Analysis of the two p97/
VCP/Cdc48p proteins of Caenorhabditis elegans and their
suppression of polyglutamine-induced protein aggregation.  J
Struct Biol 2004, 146:242-50.
19. Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ: Sup-
pression of polyglutamine-induced toxicity in cell and animal
models of Huntington's disease by ubiquilin.  Hum Mol Genet
2006, 15:1025-41.
20. Wang H, Lim PJ, Karbowski M, Monteiro MJ: Effects of overexpres-
sion of huntingtin proteins on mitochondrial integrity.  Hum
Mol Genet 2009, 18:737-52.
21. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R,
Blakely RD, Wong G: Dopaminergic neuronal loss and motor
deficits in Caenorhabditis elegans overexpressing human
alpha-synuclein.  J Neurochem 2003, 86:165-72.
22. Cao S, Gelwix CC, Caldwell KA, Caldwell GA: Torsin-mediated
protection from cellular stress in the dopaminergic neurons
of Caenorhabditis elegans.  J Neurosci 2005, 25:3801-12.
23. Kuwahara T, Koyama A, Gengyo-Ando K, Masuda M, Kowa H, Tsun-
oda M, Mitani S, Iwatsubo T: Familial Parkinson mutant alpha-
synuclein causes dopamine neuron dysfunction in transgenic
Caenorhabditis elegans.  J Biol Chem 2006, 281:334-40.
24. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu
K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Mar-
sischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S:
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues
neuron loss in Parkinson's models.  Science 2006, 313:324-8.
25. Kuwahara T, Koyama A, Koyama S, Yoshina S, Ren CH, Kato T, Mitani
S, Iwatsubo T: A systematic RNAi screen reveals involvement
of endocytic pathway in neuronal dysfunction in alpha-synu-
clein transgenic C. elegans.  Hum Mol Genet 2008, 17:2997-3009.
26. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA:
Hypothesis-based RNAi screening identifies neuroprotective
genes in a Parkinson's disease model.  Proc Natl Acad Sci USA
2008, 105:728-33.
27. van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen
EA: C. elegans model identifies genetic modifiers of alpha-
synuclein inclusion formation during aging.  PLoS Genet 2008,
4(3):e1000027.
28. Dillin A, Hsu AL, Arantes-Oliveira N, Lehrer-Graiwer J, Hsin H, Fra-
ser AG, Kamath RS, Ahringer J, Kenyon C: Rates of behavior and
aging specified by mitochondrial function during develop-
ment.  Science 2002, 298:2398-401.
29. Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G: A sys-
tematic RNAi screen identifies a critical role for mitochon-
dria in C. elegans longevity.  Nat Genet 2003, 33:40-8.
30. Vattemi G, Nogalska A, King Engel W, D'Agostino C, Checler F,
Askanas V: Amyloid-beta42 is preferentially accumulated in
muscle fibers of patients with sporadic inclusion-body myosi-
tis.  Acta Neuropathol 2009, 117:569-74.
31. Link CD: Expression of human beta-amyloid peptide in trans-
genic  Caenorhabditis elegans.  Proc Natl Acad Sci USA 1995,
92:9368-72.
32. Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis
CA, Klunk WE: Visualization of fibrillar amyloid deposits in liv-
ing, transgenic Caenorhabditis elegans animals using the sen-
sitive amyloid dye, X-34.  Neurobiol Aging 2001, 22:217-26.
33. Fay DS, Fluet A, Johnson CJ, Link CD: In vivo aggregation of beta-
amyloid peptide variants.  J Neurochem 1998, 71:1616-25.
34. Fonte V, Kapulkin V, Taft A, Fluet A, Friedman D, Link CD: Interac-
tion of intracellular beta amyloid peptide with chaperone
proteins.  Proc Natl Acad Sci USA 2002, 99:9439-44.
35. Fonte V, Kipp DR, Yerg J 3rd, Merin D, Forrestal M, Wagner E, Rob-
erts CM, Link CD: Suppression of in vivo beta-amyloid peptide
toxicity by overexpression of the HSP-16.2 small chaperone
protein.  J Biol Chem 2008, 283:784-91.
36. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A: Opposing
activities protect against age-onset proteotoxicity.  Science
2006, 313:1604-10.
37. Steinkraus KA, Smith ED, Davis C, Carr D, Pendergrass WR, Sutphin
GL, Kennedy BK, Kaeberlein M: Dietary restriction suppresses
proteotoxicity and enhances longevity by an hsf-1-dependent
mechanism in Caenorhabditis elegans.  Aging Cell 2008,
7:394-404.
38. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Saha-
gan BG: Gene expression analysis in a transgenic Caenorhab-
ditis elegans Alzheimer's disease model.  Neurobiol Aging 2003,
24:397-413.
39. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD,
Luo Y: Amyloid-beta-induced pathological behaviors are sup-
pressed by Ginkgo biloba extract EGb 761 and ginkgolides in
transgenic Caenorhabditis elegans.  J Neurosci 2006, 26:13102-13.
40. Florez-McClure ML, Hohsfield LA, Fonte G, Bealor MT, Link CD:
Decreased insulin-receptor signaling promotes the
autophagic degradation of beta-amyloid peptide in C. ele-
gans.  Autophagy 2007, 3:569-80.
41. Stanhill A, Haynes CM, Zhang Y, Min G, Steele MC, Kalinina J, Mar-
tinez E, Pickart CM, Kong XP, Ron D: An arsenite-inducible 19S
regulatory particle-associated protein adapts proteasomes
to proteotoxicity.  Mol Cell 2006, 23:875-85.
42. Yun C, Stanhill A, Yang Y, Zhang Y, Haynes CM, Xu CF, Neubert TA,
Mor A, Philips MR, Ron D: Proteasomal adaptation to environ-
mental stress links resistance to proteotoxicity with longev-
ity in Caenorhabditis elegans.  Proc Natl Acad Sci USA 2008,
105:7094-9.
43. Hassan WM, Merin DA, Fonte V, Link CD: AIP-1 ameliorates
beta-amyloid peptide toxicity in a Caenorhabditis elegans
Alzheimer's disease model.  Hum Mol Genet 2009, 18:2739-47.
44. Link CD: C. elegans models of age-associated neurodegenera-
tive diseases: lessons from transgenic worm models of
Alzheimer's disease.  Exp Gerontol 2006, 41:1007-13.
45. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL,
Barnham KJ, Cherny RA, Bush AI: The Caernorhabditis elegans
Abeta1-42 model of Alzheimer's disease predominantly
expresses Abeta3-42.  J Biol Chem 2009, 284(34):22697-702.
46. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S:
Dominant and differential deposition of distinct beta-amy-
loid peptide species, A beta N3(pE), in senile plaques.  Neuron
1995, 14:457-66.
47. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pick-
ering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adam-
son J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de
Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM,
Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J,
Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd
PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J,
Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van
Swieten J, Mann D, Lynch T, Heutink P: Association of missensePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Neurodegeneration 2009, 4:38 http://www.molecularneurodegeneration.com/content/4/1/38
Page 13 of 13
(page number not for citation purposes)
and 5'-splice-site mutations in tau with the inherited demen-
tia FTDP-17.  Nature 1998, 393:702-5.
48. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L,
Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD: Tau is
a candidate gene for chromosome 17 frontotemporal
dementia.  Ann Neurol 1998, 43:815-25.
49. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B:
Mutation in the tau gene in familial multiple system tauopa-
thy with presenile dementia.  Proc Natl Acad Sci USA 1998,
95:7737-41.
50. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ,
Schellenberg GD: Neurodegeneration and defective neuro-
transmission in a Caenorhabditis elegans model of tauopathy.
Proc Natl Acad Sci USA 2003, 100:9980-5.
51. Kraemer BC, Schellenberg GD: SUT-1 enables tau-induced neu-
rotoxicity in C. elegans.  Hum Mol Genet 2007, 16:1959-71.
52. Guthrie CR, Schellenberg GD, Kraemer BC: SUT-2 potentiates
tau-induced neurotoxicity in Caenorhabditis elegans.  Hum Mol
Genet 2009, 18:1825-38.
53. MacMorris M, Kumar M, Lasda E, Larsen A, Kraemer B, Blumenthal T:
A novel family of C. elegans snRNPs contains proteins associ-
ated with trans-splicing.  Rna 2007, 13:511-20.
54. Suntharalingam M, Alcazar-Roman AR, Wente SR: Nuclear export
of the yeast mRNA-binding protein Nab2 is linked to a direct
interaction with Gfd1 and to Gle1 function.  J Biol Chem 2004,
279:35384-91.
55. Kelly SM, Pabit SA, Kitchen CM, Guo P, Marfatia KA, Murphy TJ, Cor-
bett AH, Berland KM: Recognition of polyadenosine RNA by
zinc finger proteins.  Proc Natl Acad Sci USA 2007, 104:12306-11.
56. Kraemer BC, Burgess JK, Chen JH, Thomas JH, Schellenberg GD:
Molecular pathways that influence human tau-induced
pathology in Caenorhabditis elegans.  Hum Mol Genet 2006,
15:1483-96.
57. Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mitani S,
Ihara Y: Progressive neurodegeneration in C. elegans model of
tauopathy.  Neurobiol Dis 2005, 20:372-83.
58. Brandt R, Gergou A, Wacker I, Fath T, Hutter H: A Caenorhabditis
elegans  model of tau hyperphosphorylation: induction of
developmental defects by transgenic overexpression of
Alzheimer's disease-like modified tau.  Neurobiol Aging 2009,
30:22-33.
59. Hammarlund M, Jorgensen EM, Bastiani MJ: Axons break in ani-
mals lacking beta-spectrin.  J Cell Biol 2007, 176:269-75.
60. Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, Shibasaki H,
Ishii N: Oxidative stress causes abnormal accumulation of
familial amyotrophic lateral sclerosis-related mutant SOD1
in transgenic Caenorhabditis elegans.  Hum Mol Genet 2001,
10:2013-23.
61. Wang J, Farr GW, Hall DH, Li F, Furtak K, Dreier L, Horwich AL: An
ALS-linked mutant SOD1 produces a locomotor defect asso-
ciated with aggregation and synaptic dysfunction when
expressed in neurons of Caenorhabditis elegans.  PLoS Genet
2009, 5(1):e1000350.
62. Gidalevitz T, Krupinski T, Garcia S, Morimoto RI: Destabilizing
protein polymorphisms in the genetic background direct
phenotypic expression of mutant SOD1 toxicity.  PLoS Genet
2009, 5(3):e1000399.
63. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH,
Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwat-
subo T, Moore L, Goldstein L, Cookson M, Wolozin B: LRRK2
modulates vulnerability to mitochondrial dysfunction in
Caenorhabditis elegans.  J Neurosci 2009, 29:9210-8.
64. Park KW, Li L: Cytoplasmic expression of mouse prion protein
causes severe toxicity in Caenorhabditis elegans.  Biochem Bio-
phys Res Commun 2008, 372:697-702.
65. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham
HD: Up-regulation of protein chaperones preserves viability
of cells expressing toxic Cu/Zn-superoxide dismutase
mutants associated with amyotrophic lateral sclerosis.  J Neu-
rochem 1999, 72:693-9.
66. Link CD, Fonte V, Hiester B, Yerg J, Ferguson J, Csontos S, Silverman
MA, Stein GH: Conversion of green fluorescent protein into a
toxic, aggregation-prone protein by C-terminal addition of a
short peptide.  J Biol Chem 2006, 281:1808-16.
67. Mello CC, Kramer JM, Stinchcomb D, Ambros V: Efficient gene
transfer in C. elegans: extrachromosomal maintenance and
integration of transforming sequences.  Embo J 1991,
10:3959-70.
68. Wilm T, Demel P, Koop HU, Schnabel H, Schnabel R: Ballistic
transformation of Caenorhabditis elegans.  Gene 1999, 229:31-5.
69. Jackstadt P, Wilm TP, Zahner H, Hobom G: Transformation of
nematodes via ballistic DNA transfer.  Mol Biochem Parasitol
1999, 103:261-6.
70. Frokjaer-Jensen C, Davis MW, Hopkins CE, Newman BJ, Thummel
JM, Olesen SP, Grunnet M, Jorgensen EM: Single-copy insertion of
transgenes in Caenorhabditis elegans.  Nat Genet 2008,
40:1375-83.
71. Duerr JS: Immunohistochemistry.  WormBook 2006:1-61.
72. Locke CJ, Fox SA, Caldwell GA, Caldwell KA: Acetaminophen
attenuates dopamine neuron degeneration in animal models
of Parkinson's disease.  Neurosci Lett 2008, 439:129-33.
73. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC:
Identification of potential therapeutic drugs for huntington's
disease using Caenorhabditis elegans.  PLoS One 2007, 2(6):e504.
74. Pulak R: Techniques for analysis, sorting, and dispensing of C.
elegans on the COPAS flow-sorting system.  Methods Mol Biol
2006, 351:275-86.
75. Burns AR, Kwok TC, Howard A, Houston E, Johanson K, Chan A,
Cutler SR, McCourt P, Roy PJ: High-throughput screening of
small molecules for bioactivity and target identification in
Caenorhabditis elegans.  Nat Protoc 2006, 1:1906-14.
76. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, Stanley EF,
McCourt P, Cutler SR, Roy PJ: A small-molecule screen in C. ele-
gans yields a new calcium channel antagonist.  Nature 2006,
441:91-5.
77. Boyd WA, Smith MV, Kissling GE, Freedman JH: Medium- and high-
throughput screening of neurotoxicants using C. elegans.
Neurotoxicol Teratol 2009 in press.
78. Yanik MF, Cinar H, Cinar HN, Chisholm AD, Jin Y, Ben-Yakar A:
Neurosurgery: functional regeneration after laser axotomy.
Nature 2004, 432:822.
79. Rohde CB, Zeng F, Gonzalez-Rubio R, Angel M, Yanik MF: Microflu-
idic system for on-chip high-throughput whole-animal sort-
ing and screening at subcellular resolution.  Proc Natl Acad Sci
USA 2007, 104:13891-5.
80. Chung K, Crane MM, Lu H: Automated on-chip rapid micros-
copy, phenotyping and sorting of C. elegans.  Nat Methods 2008,
5:637-43.
81. Ben-Yakar A, Bourgeois F: Ultrafast laser nanosurgery in micro-
fluidics for genome-wide screenings.  Curr Opin Biotechnol 2009,
20:100-5.
82. Brignull HR, Moore FE, Tang SJ, Morimoto RI: Polyglutamine pro-
teins at the pathogenic threshold display neuron-specific
aggregation in a pan-neuronal Caenorhabditis elegans model.
J Neurosci 2006, 26:7597-606.